184 results on '"Franzius, Christiane"'
Search Results
2. Diagnostic Applications of Nuclear Medicine: Pediatric Cancers
3. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial
4. Bildgebung
5. Pediatric Cancers
6. Implementation and Reporting of I-123- mIBG Scintigraphy in Children and Adolescents with Neuroblastoma (Version 3) DGN-Treatment Recommendation (S1-Guideline), Status: 2/2020 AWMF-Register Number: 031-040
7. Durchführung und Befundung der 123I-mIBG-Szintigraphie bei Kindern und Jugendlichen mit Neuroblastom (Version 3) – DGN-Handlungsempfehlung (S1-Leitlinie), Stand: 2/2020 – AWMF-Registernummer: 031-040
8. Diagnostic Applications of Nuclear Medicine: Pediatric Cancers
9. Die Rolle der F-18-FDG-Positronen-Emissions-Tomographie für chirurgische Fragestellungen
10. Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany
11. Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients.
12. Optimized whole-body positron emission tomography magnetic resonance imaging sequence workflow in pediatric Hodgkin lymphoma patients.
13. Potentiale von KI und Radiomics in der onkologischen Nuklearmedizin
14. PET/CT bei Patienten mit Melanom: eine Zweiklassenversorgung? Stand der Versorgung mit PET/CT in der primären Ausbreitungsdiagnostik des Melanoms
15. Impact of PET-CT on Primary Staging and Response Control on Multimodal Treatment of Esophageal Cancer
16. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography
17. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters
18. PET/CT in paediatric oncology: indications and pitfalls
19. Diagnostic impact of 18F-FDG PET–CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound
20. PET/CT in malignant melanoma: a two‐tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT
21. Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model
22. Is PET/CT necessary in paediatric oncology?
23. Clinical Value of Parathyroid Scintigraphy with Technetium-99m Methoxyisobutylisonitrile: Discrepancies in Clinical Data and a Systematic Metaanalysis of the Literature
24. Pediatric Cancers
25. Pulmonale Aspergillose als Erstmanifestation einer septischen Granulomatose (chronic granulomatous disease, CGD) bei eineiigen weiblichen Zwillingsfrühgeborenen und Ausbreitungsdiagnostik mittels FDG-PET
26. Klinische Wertigkeit der Positronenemissionstomographie (PET) in der Diagnostik der Knochen- und Weichteiltumore 3. Interdisziplinäre Konsensuskonferenz „PET in der Onkologie“. Ergebnisse der Arbeitsgruppe Knochen- und Weichteiltumore: 3. Interdisziplinäre Konsensuskonferenz „PET in der Onkologie“. Ergebnisse der Arbeitsgruppe Knochen- und Weichteiltumore
27. Durchführung und Befundung der123 I-mIBG-Szintigraphie bei Kindern und Jugendlichen mit Neuroblastom (Version 3) – DGN-Handlungsempfehlung (S1-Leitlinie), Stand: 2/2020 – AWMF-Registernummer: 031-040.
28. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy
29. Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
30. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method
31. Baseline and interim PET‐based outcome prediction in peripheral T‐cell lymphoma: A subgroup analysis of the PETAL trial
32. The Role of Positron Emission Tomography in the Evaluation of Residual Masses After Chemotherapy for Advanced Stage Seminoma
33. Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group
34. European guideline for imaging in paediatric and adolescent rhabdomyosarcoma — joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology
35. Entwicklung eines kompetenzbasierten Lernzielkatalogs Nuklearmedizin für das Studium der Humanmedizin in Deutschland
36. 3-[ 123I]Iodo-L-α-methyl tyrosine transport into human fibroblasts and comparison with Ewing’s sarcoma cells
37. Kinetic parameters of 3-[ 123I]iodo-L-α-methyl tyrosine ([ 123I]IMT) transport in human GOS3 glioma cells
38. Characterization of 3-[ 123I]iodo-L-α-methyl tyrosine ([ 123I]IMT) transport into human Ewing’s sarcoma cells in vitro
39. Interim PET evaluation in diffuse large B-cell lymphoma employing published recommendations: Comparison of the Deauville 5-point scale and the ΔSUVmax method.
40. Interim PET evaluation in diffuse large B-cell lymphoma employing published recommendations: Comparison of the Deauville 5-point scale and the ΔSUVmax method.
41. Entwicklung eines kompetenzbasierten Lernzielkatalogs Nuklearmedizin für das Studium der Humanmedizin in Deutschland
42. End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry
43. Low Malignancy Rates in Fine-Needle Aspiration Cytologies in a Primary Care Setting in Germany
44. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany
45. Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with T Cell Lymphomas Participating in the PETAL Trial
46. Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial
47. Immunoglobulin M Heavy/Light Chain Pair Measurement Independently Predicts Clinical Outcome and Refines Prognostic Information Provided By Interim PET in Patients with Aggressive Lymphomas
48. Entwicklung eines kompetenz - basierten Lernzielkatalogs Nuklearmedizin für das Studium der Humanmedizin in Deutschland.
49. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
50. Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.